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Abstract
Acaricidal (tick) and insecticidal (flea) efficacy of systemically and cutaneously distributed ectoparasiticide products
for dogs are compared based on permethrin and fluralaner as representative molecules. Results of efficacy studies
against fleas and ticks are reviewed that show generally good to excellent results. Both externally and systemically
distributed treatments have benefits and weaknesses in potentially preventing pathogen transmission by these
arthropod vectors.
Four general properties are considered related to the goal of providing optimal reduction in the risk of vector-borne
pathogen transmission. These are:
1. Owner adherence to the recommended treatment protocol;
2. Rapid onset of activity following administration;
3. Uniform efficacy over all areas of the treated dog at risk for parasite attachment;
4. Maintenance of high efficacy throughout the retreatment interval.
In considering these four factors, a systemically distributed acaricide can offer an option that is at least as effective
as a cutaneously administered acaricide with regard to the overall goal of reducing the risk of vector-borne
pathogen transmission.
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Background
Over the last 25 years, considerable advances have been
made in the discovery and development of ectoparasiti-
cide products for dogs. This has resulted in an enormous
increase in the number of available products to either
treat dogs against ectoparasites or to prevent develop-
ment of ectoparasite populations in the household en-
vironment. One consequence of this development is an
on-going debate regarding the relative merits of using
either an ectoparasite control medicine that is distributed
cutaneously on the dog skin surface or an ectoparasiticide
that is distributed systemically by the dog’s blood circula-
tion. This discussion regarding active ingredient distribu-
tion is independent of questions regarding the mode of
administration, because systemically distributed active in-
gredients may be administered orally, on the skin surface,
or by injection. On the other hand, all currently available
cutaneously distributed products are exclusively adminis-
tered externally, on the skin surface.
The on-going debate has recently changed with the
commercial introduction of isoxazoline-class ectopara-
siticidal medicines. This new class offers systemic, pro-
longed and highly specific efficacy against multiple
genera and species of ectoparasitic arthropods and
delivers highly successful control compared to earlier
compounds. There are presently three medicines in this
class that have received approval for use on dogs: flura-
laner (Bravecto, MSD Animal Health, Madison, USA),
afoxolaner (NexGard, Merial, Lyon, France) and sarolaner
(Simparica, Zoetis, Florham Park, USA). A notable dif-
ference between the three currently approved commercial
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isoxazoline formulations is that fluralaner offers a duration
of activity following a single dose that is nearly three times
longer compared with the other two [1–3].
The aim of this review is to reconsider the debate
between (i) the efficacy against ectoparasites and (ii)
the vector-borne disease control of systemically and
cutaneously distributed ectoparasiticides in light of the
introduction of the isoxazolines. To focus the discus-
sion, systemic and cutaneously distributed products
are compared by using a representative example medicine
for each class. Fluralaner has been chosen to represent the
systemically distributed class and the synthetic pyrethroid
permethrin has been chosen as the comparison compound
selected for the cutaneously distributed medicine. This
review of published data regarding the use of both
ectoparasiticides is intended to help veterinary parasi-
tologists and practicing veterinarians when considering
their recommendations for effective ectoparasite con-
trol in dogs.
Background on ectoparasite medications for dogs
It has long been known that certain plants, flowers, and
roots - or oils and resins extracted from them - have
measurable effects against ectoparasites [4–9]. Such ex-
tracts include pyrethrins, rotenone and others - and
purified active ingredients from these extracts have been
commercialised as ectoparasiticides for use on domestic
animals. The pyrethrins include various natural insecti-
cidal esters derived from extracts of the pyrethrum plant
Chrysanthemum cinerariifolium and related plant spe-
cies. Members of this class have been shown to have
“knock-down” properties for arthropods and a low
toxicity for mammals. “Knock down” means that treat-
ment leads to a relatively quick parasite drop off after
the parasite shows initial hyper-excitation, disorientation
and repellence that can be followed by, at a sufficient
dose, arthropod death [6, 9]. These properties led to
interest in further understanding and testing of these
ectoparasitic substances, leading to discovery of the syn-
thetic pyrethroids. These include a range of synthesized
compounds developed from the original pyrethrin moiety
that are now widely used in various formulations and in a
variety of combinations with other substances for the
control of ectoparasites of dogs, other domestic animals
and people.
In contrast to the plant origin of pyrethrins, isoxazo-
line class medicines were discovered through searches
using “libraries” of potential candidate molecules. The
candidates were analysed in batteries of sensitivity tests
looking for evidence of potent insecticidal and acaricidal
activity based on standardized in vitro and in vivo
models. Promising molecules were then evaluated for
mammalian safety before proceeding to clinical testing
for potential commercial introduction. The commercially
available isoxazoline molecules differ in their specific
chemical structure, but all are based on the central charac-
teristic isoxazoline moiety.
A brief discussion of terms used in discussing
ectoparasiticide efficacy
Comparative discussions of the properties of antipara-
sitic compounds involve the introduction of terms that
can sometimes be confusing. The most common source
reference for these definitions is the World Association for
the Advancement of Veterinary Parasitology (WAAVP)
guidelines for companion animal ectoparasiticides and
these guidelines are used here in attempting to reduce the
confusion [10]. Efficacy refers to the actual therapeutic
response produced by a product against an ectoparasite
as determined in a number of controlled studies using
infested animals. Immediate or curative efficacy means
the therapeutic effect of a product on a resident ecto-
parasite population within a defined period from treatment
within 24 – 48 h after initial treatment or re-infestation.
Persistent (residual) efficacy means the extended thera-
peutic activity of a product measured in days or weeks
(normally at time points more than 48 h following the ini-
tial treatment).
Repellency refers to the action of a product that
causes ectoparasites to avoid or leave the dog, or to fail
to feed on the dog, i.e. the ability of the compound to
prevent the parasite from attaching or migrating onto
the dog. A similar concept is the “anti-feeding” effect,
which refers to the ability of the compound to stop the
parasite from taking a meal from the dog. Three addi-
tional concepts that should be clarified are “speed of
kill”, “onset of activity” and “onset of effect”. Speed of
kill refers to the time after treatment for a product to
kill a stated percentage of the parasite population. Speed
of kill tends to decrease with time following treatment
and therefore should be discussed in reference to the
length of time elapsed after treatment of the animal.
Additionally, the length of time the parasite is exposed
to the treated animal is important in interpreting speed
of kill data. Onset of activity refers to the time taken
following first treatment of the animal before an initial
killing effect can be measured against parasites already
on the host at the time of treatment. Onset of effect re-
fers to the time taken for the proportion of parasites
killed to reach a previously specified regulatory effi-
cacy level (in Europe this is usually 90 % for ticks and
95 % for fleas) throughout the recommended treat-
ment interval.
There are generally two calculation methods used to
summarize efficacy data for statistical comparison of
experimental results between groups of test animals.
The geometric mean - a type of average indicating the
central tendency of a set of numbers - is defined as the
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nth root of the product of n numbers, while the arith-
metic mean is defined as the sum of n numbers di-
vided by n. The arithmetic mean is preferred by
registration agencies, possibly because the calculated
result tends to be more conservative in estimating effi-
cacy. The geometric mean is less influenced by outlier
numbers and therefore this measure is sometimes pre-
ferred in scientific reports evaluating ectoparasiticide
efficacy. Parasite population numbers have a tendency
to increase dramatically if a treatment is ineffective and
the geometric mean calculation is less affected in this
case. Results of studies that are calculated using the
arithmetic mean cannot be reasonably compared to re-
sults calculated using the geometric mean - unless the
result is either 100 % or 0 %, when the two calculated
means are the same.
Cutaneously distributed ectoparasiticides - using
permethrin as an example
Short description of permethrin
Permethrin, discovered in 1973 [4], is a synthetic struc-
tural derivative of the naturally occurring pyrethrins and
is classified as a Type-I pyrethroid because it lacks an
ά-cyano group. In veterinary medicine, permethrin is
widely used on dogs and various food-producing animal
species as a topically administered and cutaneously
distributed medication for control and prevention of
arthropod parasites [8, 9]. In dogs permethrin is pre-
dominantly administered as a spot-on formulation but
has also been formulated in collars [11, 12]. Permethrin
is also used to impregnate clothes and nets to protect
people from flying arthropods, an indication that is par-
ticularly valuable for reducing the risk of malaria trans-
mission in tropical and subtropical areas [13].
Permethrin is poorly soluble in water, non-volatile and
stable under the effects of light, air, acidity, alkalinity
and moisture. These properties contribute to a much
greater residual capability of permethrin compared with
natural pyrethrins. The lipophilic properties of per-
methrin provide it with an increased attraction to lipid-
containing tissues where it is rapidly metabolised through
enzymatic hydrolysis, oxidation and other conjugation
processes. This rapid metabolism contributes to the safety
of permethrin in dogs. However, cats - unlike dogs - lack
the enzyme glucuronyl transferase for conjugating per-
methrin metabolites and cannot metabolise permethrin at
the dosages in dog formulations. Consequently, any con-
tact between cats and products containing permethrin,
including contact with permethrin-treated dogs, must be
avoided. Clinical signs of toxicity in cats include hypersali-
vation, muscle tremors, cramps, hyperthermia, motility
disorders and lameness and can lead to death if the cat is
not rapidly treated [7–9].
Administration of permethrin or permethrin-containing
formulations on dogs
Permethrin formulations for dogs are often mixed with
other compounds to improve the insecticidal activity of
the combination. Examples are: indoxacarb (Activyl,
MSD Animal Health, Madison, USA); fipronil (Frontline
Tri-Act/Frontect, Merial, Lyon, France) and imidacloprid
(Advantix, Bayer Animal Health, Leverkusen, Germany).
Some permethrin combinations for dogs also contain an
Insect Growth Regulator (IGR), e.g. permethrin, dinote-
furan and pyripoxyfen (abbreviated as DPP) (Vectra 3D,
Ceva Santé Animale, Libourne, France). These formula-
tions, whether a single active or a combination, are
typically administered directly onto the skin (“spot-on”)
between the shoulder blades or on the back after ap-
propriately parting the hair. There is limited transder-
mal absorption, less than 2 % through mammalian skin,
after administration [8, 13]. The lipophilic nature of
permethrin means that it is almost insoluble in water
[14] and therefore topical formulations can have an oily
consistency from the use of appropriate solvents.
Mode of action on arthropods
Permethrin works after contact with the arthropod and
absorption into the arthropod either directly through the
outer cuticle or through ingestion during feeding on the
host. The lipophilic properties of permethrin lead to dis-
tribution along the arthropod nervous system. Permeth-
rin interferes with the voltage-gated sodium channels of
neurons by slowing down the activation and inactivation
process of the sodium channel gates and significantly
prolonging sodium ion influx. This results in continuous
nerve discharges causing restlessness, incoordination,
tremor, paralysis and respiratory failure and eventually
arthropod death [8, 9, 15].
Pyrethroids are much more potent to arthropods than
mammals (other than cats) as seen by comparing the
difference in comparative lethal doses (LD50). The rela-
tive potency of permethrin comparing its toxicity for
insects with its toxicity to rats is approximately 1400×
higher [5], thus underlining the high selective killing po-
tential for arthropods. Additionally, at lower tempera-
tures the potency of pyrethroids increases, adding to
the selectivity for poikilothermic insects. The much
slower metabolism of permethrin by ester hydrolysis
and various oxidase functions in arthropods compared
with mammals further increases the selective toxicity
for arthropods over mammals, with the notable excep-
tion of the cat as described earlier.
Permethrin distribution on dogs
Permethrin and permethrin-containing spot-on formula-
tions are designed in a way that the active ingredients
will spread cutaneously on the dog’s skin surface by local
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tissue-dependent migration through continuity from the
point of administration through the hair coat along the
stratum corneum with the objective of eventually covering
the entire body surface. Experiments specifically under-
taken in a small number of dogs to demonstrate this cove-
ring objective under specified laboratory conditions have
shown that most - but not necessarily all - parts of the
dog’s surface had been covered to the same extent and
concentration [16, 17]. The lipophilic permethrin is de-
tectable in the hair coat and stratum corneum after appli-
cation, but cannot pass through the stratum corneum, nor
through the rather hydrophilic dermis [17, 18]. Permeth-
rin is typically applied - according to body weight - in
either one or two spots on the dorsal back of the dog and
it is possible under normal home treatment conditions
that more distant regions of the body may not receive the
same coverage as places closer to the application site.
Some distant body parts (distal parts of legs, parts of the
belly) were not fully covered by permethrin migration in
one study [16]. An experimental study on body distribu-
tion of permethrin after topical application using six dogs
[17] revealed markedly lower and highly variable permeth-
rin concentrations in the stratum corneum of the hind legs
compared with an area on the dorsal back of the dog,
about 10 cm from the drug application site, starting from
the first day after treatment. Also, some hair samples
taken on day 14 and day 28 after treatment from the hind
legs of dogs in this study showed significantly lower per-
methrin values than hair samples from the back. Addition-
ally, overall permethrin concentrations decreased faster
over the 28 day study period in both the hair and the
stratum corneum of the hind legs compared with the back.
These findings suggest that factors affecting the dog’s coat
structure and physiology - such as continuous stratum
corneum desquamation, grooming behaviour and environ-
mental aspects (sun exposure, bathing and shampooing,
swimming) could all contribute to a varying degree of
superficial dermal abrasion and permethrin removal.
There could be an impact of constant hair coat and
skin changes (e.g. stratum corneum desquamation) and
dog activity (e.g. frequent wetting of the feet and lower
limbs during outdoor activity) on the speed and extent
of superficial permethrin migration. Thus, the efficacy
of topically administered and distributed permethrin
products could be reduced in areas distant from the ap-
plication site. Field trial results in privately owned dogs
[19] showed that the highest (surviving) immature tick
counts on day 28 after imidacloprid 10 %/permethrin
50 % treatment were seen on the legs. This observation
underlined the potential for a greater comparative rate
of loss of active ingredient from areas such as the legs.
Shampoo bathing is known to effectively remove per-
methrin from the coat, and thus is an important part of
the recommended treatment protocol for exposed cats.
Therefore, it is reasonable to believe that routine bath-
ing and swimming in the normal life of a household
dog will influence the duration of effect of permethrin
subsequent to topical application. These types of effects
could result in diminished efficacy and could help to
explain the considerable variation in published per-
methrin efficacy data, particularly towards week 4 after
treatment.
Efficacy of permethrin against ticks
The tick killing effect within 24–48 h after treatment or
re-infestation is sometimes called “immediate” or “cura-
tive” efficacy, although other terms are also used such as
“knock-down” effect [10, 20]. The rapid cuticular pene-
tration and high drug accumulation of permethrin in
arthropod tissue [13, 21] generally contribute to a rapid
killing efficacy [22]. Therefore, permethrin application
usually provides a strong immediate killing effect after
initial arthropod exposure.
Permethrin and permethrin-combination products have
proven to be effective against various tick species on dogs,
following either artificial or natural infestations. Multiple
efficacy studies are described in this review, rather than
tabulated, because the use of differing methodologies and
terminology in the studies would make interpretation of a
table very complex. Instead, a simplified graphic represen-
tation is used to pull together data from all 16 published
studies that provide challenge data meeting basic stan-
dards of quality and duration (Fig. 1; see the Discussion
section of this paper for further explanation) [16, 23–33].
Efficacy of a topical 65 % permethrin - formulation
(Defend Exspot, MSD Animal Health, Madison, USA)
on day 1 after treatment was between 75 % (against
Dermacentor variabilis) and 100 % (against Ixodes
dammini – now renamed Ixodes scapularis) in small
(< 15 kg) dogs using a “lower dosage” and was 100 %
in heavier (> 15 kg) dogs using a “higher dosage” [16].
Efficacies against Rhipicephalus sanguineus (sensu
lato) on day 3 after topical administration of the same
product were 70 % (small dogs) and 49 % (heavier dogs)
compared to 96 and 90 %, respectively on day 7 post-
treatment. The same 65 % permethrin formulation was
used in two other trials [23, 24] and demonstrated effica-
cies of 96.3 % on day 2 and > 99 % on day 7 after treat-
ment when dogs were exposed for 2 h to adult Ixodes
ricinus. Permethrin killed adult Dermacentor reticulatus
ticks and also killed 100 % of unfed nymphs and larvae
within 48 h after topical administration and also impaired
the embryonic development of eggs from exposed adult
female ticks [34, 35].
Many efficacy trials have been conducted with combi-
nations of permethrin and other active ingredients. A
combination of imidacloprid 10 %/permethrin 50 %
spot-on (Advantix, Bayer Animal Health, Leverkusen,
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Germany) demonstrated a “curative” efficacy of 74 %
against experimental adult R. sanguineus (s.l.) and of
67 % against I. ricinus infestations at 2 days post-
treatment [25]. The 48 h post-treatment efficacy of the
DPP topical combination (dinotefuran 4.95 %/permethrin
36.08 %/pyriproxifen 0.44 %) (Vectra 3D, Ceva Santé
Animale, Libourne, France) was 57.1 % and the efficacy of
the combination imidacloprid 8.8 %/permethrin 44.0 %
(K 9 Advantix, Bayer Animal Health, Leverkusen,
Germany) was 54.3 %, against adult R. sanguineus (s.l.)
The 24 h post-treatment efficacy was only 11.9 % for
DPP and 16.7 % for imidacloprid/permethrin [26].
These low efficacies were thought to be associated with
ticks that were already attached at the time of treat-
ment and that therefore received comparatively less
contact with the active ingredient because they did not
need to find an attachment site. However, by day 8
post-treatment, the efficacy of both treatments in-
creased to > 99 % at 24 and 48 h post-challenge. In an-
other study, the same DPP formulation (permethrin
36.08 %, Vectra 3D, Ceva Santé Animale, Libourne,
France) had an efficacy of 79.9 % against R. sanguineus
(s.l.) on dogs in a laboratory challenge at 48 h after
spot-on treatment application [27].
Field studies with an 8.8 % imidacloprid/44.0 % per-
methrin formulation (K9 Advantix, Bayer Animal Health,
Leverkusen, Germany) found that the 48 h post-treatment
efficacy was 93.5 % against adult Amblyomma ameri-
canum and 88.54 % against adult R. sanguineus (s.l.)
ticks [28]. Significant acaricidal effects (compared with
untreated controls) of spot-on permethrin or
permethrin-combinations were measured at 6 h after
treatment against adult D. reticulatus, but higher effi-
cacy rates were not observed until 24–48 h post-
treatment. A different approach of calculation was used
in this study and the exact efficacy data are not speci-
fied [36].
A combination of 50.48 % permethrin and 6.76 % fipronil
(Frontline Tri-Act/Frontect, Merial, Lyon, France) in a
laboratory challenge had efficacy of 94.4 % and 100 %
against R. sanguineus, 100 % against I. ricinus, and > 99 %
against adult D. reticulatus two days after treatment [29].
Similarly, 98 % efficacy of a 54.5 % permethrin/6.1 % fipro-
nil combination (Effitix, Virbac, Carros, France) was dem-
onstrated against experimental adult I. ricinus infestation
two days post-treatment [30]. The contribution of per-
methrin to these results cannot be quantified given the
known acaricidal activity of fipronil.
The above studies show that acaricidal efficacy varies
considerably following permethrin administration to
dogs. The varying efficacy rates observed between dif-
ferent tick species do not apparently correlate with the
Fig. 1 A summary analysis of all 16 published permethrin efficacy studies [16, 23–33] meeting quality and duration standards against ticks
(genera are Ixodes, Rhipicephalus, Dermacentor and Amblyomma) on healthy dogs to illustrate the range of potential efficacies expected in field use
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concentration of permethrin in the applied formulation.
Several studies also show that acaricidal efficacy of per-
methrin can be weak within the first 48 h after adminis-
tration, and this was observed in studies with both
mono-substance formulations and in combinations
with active ingredients including imidacloprid or dino-
tefuran/pyriproxifen.
A laboratory challenge study observed 100 % efficacy
against adult R. sanguineus (s.l.) and D. variabilis after
3 h exposure on day 3 following administration of a
combination formulation containing permethrin 44 %/
imidacloprid 8.8 %. This study also reported efficacy of
only 88.6 % against adult A. americanum and 92.9 %
against adult I. scapularis [31, 32]. However, for the lat-
ter tick species, 100 % efficacy was reached after 24 h
tick exposure suggesting that timely and extended per-
methrin contact is essential for increased acaricidal
efficacy.
The variety of study designs, tick challenges, efficacy
measurement techniques and calculation methods used
make study results summaries difficult and confusing.
However, the field conditions under which permethrin
treatments are used are equally highly variable: for ex-
ample, the infesting tick species are often not identified
and the dose may be inexpertly administered. Therefore,
an overall summary of all reported experimental results
still provides a valuable indication of the full range of ef-
ficacy that might be expected with field administration.
To prepare a visual overall summary, mean efficacy was
calculated from the 16 published studies with 4 week ef-
ficacy results (Fig. 1). In addition to the mean efficacy,
an upper and lower bound of one standard deviation
above and below is shown indicating the potential effi-
cacy range. Permethrin efficacy peaks between 7 and
14 days post-treatment and it is likely that a portion of
ticks infesting treated dogs will survive permethrin treat-
ment during the times outside this peak period. This in-
cludes the initial week following first administration and
the period of declining efficacy following day 14 after
treatment. It is much less likely, but still possible, for
ticks to survive during this peak period. The reasons for
this efficacy pattern are likely complex and include mul-
tiple host, parasite, environment and treatment related
factors. One factor is the variation in efficacy against the
same tick species isolated from different geographical
areas of tick origin: for example, one study reported 92 %
efficacy for an imidacloprid/permethrin formulation against
a D. variabilis isolate from California, whereas the com-
parative efficacy against an Oklahoma isolate of the same
tick species was only 17.5 % [37]. Differences in product
formulations and variations in skin surface distribution of
the active ingredients can also contribute to differing effi-
cacy results [38]. A comparison of the efficacy of four differ-
ent permethrin formulations - including a combination
with imidacloprid - reported non-significant slight varia-
tions [36]. Somewhat lower and more variable efficacy re-
ported on distal body locations of dogs treated with a
combination of imidacloprid 10 %/permethrin 50 %
(Advantix, Bayer Animal Health, Leverkusen, Germany)
support the hypothesis that uneven or partially uneven
distribution of active ingredients on the body surface
accounts for some efficacy variability [19]. However,
further research may be required to better understand
the factors underlying reported efficacy variation.
Long-term (preventive) efficacy against ticks and tick-
borne infections
The individual host-seeking patterns, survival strategies
and disease epidemiology of the different genera and
species of ixodiid ticks ensure that tick control com-
pounds require an extended efficacy period to ensure
successful and sustainable control of these ticks. Effective
tick control is a prerequisite for reducing the risk of trans-
mission of the associated tick-borne infections. Control
does not need to be immediate because there is a grace
period between attachment of the tick and transmission of
tick-borne organisms [39] during which time effective
acaricidal treatment can prevent infectious agent trans-
mission. Additionally, tick-borne infectious agent trans-
mission is more intricate and complex than the simple
concept of immediate injection of infectious agents
residing in the tick mouth parts. This subject will not
be reviewed in this paper; however, it is possible that
tick-borne infections may require an on-host stay/feeding/
attachment of longer than 24–48 h for successful patho-
gen transmission [40]. One study showed transmission of
Ehrlichia more rapidly following tick attachment; however,
this study used an intensive laboratory exposure model
and the transmission rate did not increase over the initial
24 h of exposure [41].
Most permethrin or permethrin-associated combina-
tions have label indications that offer both immediate
and persistent efficacy against ticks over approximately
one month following initial treatment. The duration of
the preventive efficacy may be 4 weeks, or in some
cases even 5 weeks after a single topical administration
[16, 19, 29, 36, 42]. However, some label indications
may be shorter, for example the 3 week duration of efficacy
recommended against D. reticulatus for an imidacloprid/
permethrin formulation (Advantix, Bayer Animal Health,
Leverkusen, Germany) [43].
A single spot-on administration of permethrin (Defend
Exspot, MSD Animal Health, Madison, USA) can result
in efficacy between 88 and 92 % (against adult R. san-
guineus) and 86–90 % (against adult I. dammini – now
I. scapularis) as well as between 87 and 99.5 % (against
adult I. ricinus) for a period of 28 days [16, 23, 24].
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A single topical administration of a combination of
imidacloprid 8.8 %/permethrin 44.0 % (K9 Advantix,
Bayer Animal Health, Leverkusen, Germany) was used
in experimental studies, and the following efficacies were
measured at 48 h after re-infestation: 97.6 – 91.5 %
against adult R. sanguineus (s.l.) and 100 % – 91.6 %
against adult I. ricinus over 5 weeks; ≥ 88.8 % against adult
R. sanguineus (s.l.)., ≥ 92 % against adult D. variabilis,
> 95 % against A. americanum and ≥ 96.5 % against I. sca-
pularis for a period of 28 days after treatment [25, 32].
In a comparative trial testing DPP against an imidaclo-
prid/permethrin combination for adult R. sanguineus
s.l. efficacy, the 24 h post-treatment values for imida-
cloprid 8.8 %/permethrin 44 % on day 29 (91.7 %) were
not significantly different from those of the DPP com-
bination (> 96 %) [26]. A field study in Italy confirmed
these results with efficacies of 91.6 % against adult R. san-
guineus (s.l.) and > 98 % against a co-challenge with
adult and immature R. sanguineus s.l. together at
28 days after treatment with a spot-on combination of
imidacloprid 10 %/permethrin 50 % (Advantix, Bayer
Animal Health, Leverkusen, Germany) [19]. However,
on day 7 post-treatment, the acaricidal efficacy against
adult R. sanguineus (s.l.) remained below 90 % before
increasing to > 90 % thereafter until day 28 post-
treatment.
Lower values of only 81.4 % efficacy against adult R.
sanguineus (s.l.) were detected 30 days after treatment
with imidacloprid 10 %/permethrin 50 % (Advantix,
Bayer Animal Health, Leverkusen, Germany) [44] and
also 24 h post-treatment efficacy < 90 % were measured
against adult D. reticulatus with the same topically ad-
ministered product over a 29 day study period [45].
A single topical spot-on administration of the com-
bination 6.76 % fipronil/50.48 % permethrin (Frontline
Tri-Act/Frontect, Merial, Lyon, France) to dogs under
laboratory conditions, resulted in preventive efficacy
of > 96 % against R. sanguineus (s.l.)., > 99 % against I.
ricinus and > 99 % against D. reticulatus at 48 h fol-
lowing re-infestation over a study period of 28 to
30 days [29, 33]. Similarly, protection against I. ricinus
at 48 h post-infestation ranged between 93 % on day 30
and 95 % on day 37 after administration following a single
spot-on administration of a combination of 6.1 % fipronil/
54.5 % permethrin (Effitix, Virbac, Carros, France) [31].
The reported persistent efficacies of permethrin or
permethrin-combination products show that permethrin
is likely to provide a considerable preventive potential
against arthropod transmitted infections. However, effi-
cacies are less than 100 % at most time points following
treatment. Therefore, permethrin treatment protocols
should be considered to reduce the risk of transmis-
sion, but do not completely eliminate this risk. In a
field evaluation on the prevention of tick bites in dogs
with a 10 % imidacloprid/50 % permethrin combination
(Advantix, Bayer Animal Health, Leverkusen, Germany), it
was found that treatment application once or twice
monthly led to a highly significant 95.57 % reduction of
the risk of Ehrlichia canis transmission in an endemic area
in southern Italy [46]. Continuous treatment of young
dogs in a R. sanguineus (s.l.) - endemic shelter by applica-
tion of a 10 % imidacloprid/50 % permethrin combination
(Advantix, Bayer Animal Health, Leverkusen, Germany)
every 21 ± 2 days over one year, produced an overall tick
efficacy of 97.9 % [47]. The reductions in incidence density
were: 94.6 % (E. canis), 94.4 % (Babesia spp.) and 81.8 %
(Anaplasma platys), when treated dogs were compared
with untreated control dogs. Post-treatment tick efficacy
in another study ranged between 96.1 and 98.9 % for a
period of 4 weeks following spot-on administration of
imidacloprid 10 %/permethrin 50 % (Advantix, Bayer
Animal Health, Leverkusen, Germany) against E. canis-in-
fected R. sanguineus [48]. Babesia canis transmission by
D. reticulatus ticks was prevented for 28 days following
spot-on administration of a 54.5 % permethrin - 6.1 %
fipronil combination (Effitix,Virbac, Carros, France) [49].
Other studies have documented similar protective
efficacy rates against Anaplasma phagocytophilum, A.
platys, or Borrelia burgdorferi following spot-on admin-
istration of permethrin or permethrin combinations to
dogs [50–52]. In summary, these studies confirm that
permethrin treatment can dramatically reduce, but not
eliminate the risk of tick-borne pathogen transmission.
Repellent (mechanism/potential) effect and anti-feeding
Permethrin exerts a potent repellent effect against a
variety of arthropods including ticks [23]. This effect
may originate from the contact chemoreception channel
found on receptor cells in sensilla on the ventral side of
the arthropod tarsus [53]. Therefore, the primary repellent
activity of pyrethroids would be via contact irritancy
rather than the “space-repellency” demonstrated for Aedes
aegypti [54, 55] now more commonly known as the
“anti-feeding” effect. It is not clear whether anti-feeding
in ticks is a chemical process directly limiting the feeding
behaviour or whether another mechanism is involved.
Repelled ticks may survive more easily than previously
thought [31], because only 8.3 % of moribund or apparently
dead A. americanum ticks at 3 h after a 10 min exposure to
imidacloprid/permethrin 21 days after treatment could still
be considered dead or moribund 24 h later. Nevertheless,
reported repellency results are performed under variable
conditions and there is a lack of standardized protocols
[56]. The main sources of variability between studies are
the length of time of tick exposure to the treated animal
and the methods of tick collection following exposure to
the treatment [57].
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Repellency (duration)
A single administration of 65 % permethrin spot-on
(Defend Exspot, MSD Animal Health, Madison, USA)
in laboratory challenge studies led to significant repellent
activities against adult I. ricinus measured following ex-
posure for 2 h at either 2 or 7 days after treatment and
also over a period of at least 4 weeks compared with either
untreated controls, fipronil treated dogs or selamectin
treated dogs [23, 24]. Although this formulation contains
a higher permethrin concentration, the lower volume ap-
plied to the dog results in a dose of active ingredient that
is equivalent to the dose delivered with lower strength for-
mulations. Experimental challenge trials measured a
repellent-like effect (a term used in this study to describe
an apparent rapid irritation effect) of 83 % for a single imi-
dacloprid 8.8 %/permethrin 44.0 % (K9 Advantix, Bayer
Animal Health, Leverkusen, Germany) spot-on treatment
after a 10 min exposure of R. sanguineus (s.l.) 3 days after
treatment that decreased to < 60 % on days 7, 14, 21, 28.
The repellent-like effect was between 93 and 63 % for D.
variabilis; between 86 and 68 % for A. americanum; and
between 72 and 52 % for I. scapularis on these same days
[31, 32].
Similar results were reported in a trial evaluating the
repellent activity of a fipronil-permethrin combination
(Frontline Tri-Act/Frontect, Merial, Lyon, France) against
D. reticulatus, with repellency rates after a 4 h exposure of
56.5–73.5 %; after 12 h of 76.3–92.9 %; and after 24 h of
83.9–96.5 %. In the same experimental set-up, prevention
of attachment ranged between 64.1 and 79.7 % at 4 h post
exposure, between 79.1 and 94.2 % at 12 h post-challenge
and between 84.2 and 99.6 % at 24 h post-challenge for up
to 4 weeks [33].
Efficacy against fleas
The “knock-down effect” is the most important action of
permethrin against insects and this is caused by rapid
penetration of permethrin through the arthropod cuticle
[21]. This subsequently causes selective inhibition of
specific cell functions without immediately killing the in-
sect. Sodium channels, for example, can retain selectivity
for sodium ions and conductance after exposure to py-
rethroids. As a consequence, following permethrin ex-
posure cells can either function normally in a new state
of hyperexcitability or - with exposure to a higher per-
methrin dose - the cell membrane will depolarize and
there will be a conduction block followed by repetitive
nerve discharges. This will lead to loss of function and
an accelerated speed of kill observed macroscopically as
“knock-down” or quick death of the insect [8, 16]. This
“knock-down” or “immediate therapeutic effect” should
be assessed at either 24 (European Medicines Agency)
or 72 h (WAAVP) post-treatment [10, 20] and the
“speed of kill” can also be more precisely determined or
characterized by additional counts at 4, 8, or 12 h post-
treatment exposure.
Of course, successful flea control can only be achieved
with “persistent” efficacy throughout an extended period
because of the environmental life stages components of
the flea life cycle. Relatively few published studies are
available on the persistent efficacy of permethrin against
fleas as a mono-substance, but there are many studies
on permethrin-combinations against fleas and a few on
other insects.
Post- treatment Ctenocephalides felis efficacy 72 h after
Defend Exspot (MSD Animal Health, Madison, USA) ap-
plication using a dose according to the size of the dog was
93 % for dogs less than 15 kg, and 92 % for dogs over
15 kg [16]. Persistent flea adulticidal efficacy of 99.4 % was
seen within 24 h and larvicidal efficacy of 99.2 % against
C. felis larvae on day 3 after 12 h permethrin exposure
(Advantix, Bayer Animal Health, Leverkusen, Germany)
[25]. An adulticidal effect against C. canis of > 99 % was
seen following 48 h exposure to a 4.95 % dinotefuran,
36.08 % permethrin and 0.44 % pyriproxifen (Vectra 3D,
Ceva Santé Animale, Libourne, France)) topical treatment
[58]. The same combination product killed 12.7 % of C.
felis within the first 5 min after topical treatment and the
average insecticidal efficacy of this combination was 86 %
at 1 h and 95.3 % at 4 h after infestation [59]. Dogs treated
with a combination of fipronil and permethrin (Frontline
Tri-Act/Frontect, Merial, Lyon, France) showed efficacy
of >99 % at 6 and 24 h after weekly challenges for up to
1 month [60].
A summary of five separate studies reported that a
single topical treatment with a combination of 6.76 %
fipronil/50.48 % permethrin (Frontline Tri-Act/Frontect,
Merial, Lyon, France) significantly reduced the number
of adult C. felis between 98.4 and 100 % at 24 and 48 h
post-treatment or post-infestation [61]. This level of effi-
cacy cannot be attributed to just the permethrin in the
combination, and this immediate efficacy is apparently
greater than observed in other studies following treat-
ment with permethrin-containing combinations. Even at
this level of efficacy there are still a few fleas surviving
treatment with permethrin and permethrin-combination
medications.
Repellent activity against fleas
Flea repellency, unlike tick repellency, is difficult to ap-
propriately define and measure because fleas attack and
bite so rapidly after arriving on the host. Adult cat fleas
begin feeding almost immediately once they find a host,
with many fleas feeding within minutes. In one study,
25–60 % of fleas were blood fed within 5 min and in
another study the volume of blood consumed by fleas
was quantifiable within 5 min. Feeding is so rapid that
partially digested blood can be defecated in as little as
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2–6 min after fleas acquire a host [62]. Specific studies
on the residual activity against fleas in both the USA
and Europe found that, despite appropriate flea treatment
using a medicine with both insecticidal and repellent
products, up to 92 % of infesting fleas will bite and con-
sume at least some blood before being killed [62, 63].
Therefore the primary objective of flea treatment is to
rapidly reduce flea numbers leading to elimination of the
population in the household, rather than to prevent newly
arriving fleas from taking an immediate bite.
Persistent efficacy against fleas
Treatment with permethrin alone (Defend Exspot, MSD
Animal Health, Madison, USA) achieved a C. felis effi-
cacy at 72 h post-treatment of 93 % for dogs < 15 kg and
92 % for dogs > 15 kg. The efficacy for both groups of
dogs was > 93 % at all time points during the 4 weeks
[16]. It is likely that treatment of dogs with permethrin
alone does not achieve the efficacy level required for
effective persistent flea control. Just as with tick efficacy
studies, there are many more studies that measure per-
sistent flea efficacy with permethrin combination products
than with permethrin alone. However, the interpretation
of these flea studies is more complex because combination
ingredients are included for their potent insecticidal or
insect growth regulatory activity. Therefore, these study
results are not summarized here because it is impossible
to know how much of the activity should be attributed to
permethrin rather than the other active ingredients.
Ectoparasite control via a systemically distributed drug
using fluralaner as an example
Short description of fluralaner
Fluralaner is a novel, recently developed systemically
distributed molecule of the isoxazoline class with a
highly selective ectoparasiticidal activity achieved through
blocking arthropod γ-aminobenzoic acid (GABA) and
glutamate-ligand gated chloride channels [64–67]. It is a
non-competitive GABA-receptor antagonist with a high
selective toxicity for arthropod neurons over mammalian
neurons [67–69]. In vitro studies have indicated that
fluralaner exhibits a many fold better arthropod specific
GABA-gated chloride channel inhibition than fipronil
[65]. By contrast, fluralaner blocking activity on rat
GABA receptors was very weak and a fluralaner dose
more than 5× the maximum recommended oral clinical
dose was well tolerated by dogs [70]. Fluralaner is well
tolerated by young dogs (≥ 8 weeks) and by collies carry-
ing a deletion mutation of the Multi-Drug-Resistance gene
[70, 71]. Fluralaner is not toxic for cats and is commer-
cially available as a topical formulation for use on this
species.
Fluralaner (Bravecto, MSD Animal Health, Madison,
USA) is rapidly absorbed after oral administration and
reaches maximum plasma concentrations on average
within 24 h and is quantifiable in plasma for up to
112 days after a single oral administration [67]. Absorp-
tion is slightly slower following topical administration
[72] and the depletion curve may be slightly longer.
Fluralaner has a relatively high apparent volume of body
distribution and a low clearance followed by a long
elimination half-life. These properties account for the
prolonged activity of this compound against ticks and
fleas after a single oral dose [67]. Elimination is primarily
hepatic with essentially no detection of excretion through
renal filtration [67].
Fluralaner administration to dogs
Fluralaner is presented as either a palatable chewable
tablet (Bravecto Chew, MSD Animal Health, Madison,
USA) or as a topical solution (Bravecto Spot-On, MSD
Animal Health, Madison, USA), with both presentations
dosed according to the weight of the dog. Gastrointes-
tinal absorption after oral administration is sufficiently
rapid that onset of activity against fleas can be detected
at 2 h following oral administration [67, 73].
The area under the curve (AUC) and maximum plasma
concentrations (Cmax) were increased in dogs fed at the
time of treatment compared with dogs fasted for the pre-
vious day, indicating that administration at the time of
feeding increases bioavailability of the oral formulation
(Bravecto, MSD Animal Health, Madison, USA) [74], al-
though this is not a factor affecting systemic bioavailability
after topical administration. Concurrent treatment with
either milbemycin - praziquantel, a deltamethrin collar or
therapeutic doses of ivermectin were well tolerated by
treated dogs and did not lead to observed treatment asso-
ciated adverse reactions [75–77].
Mechanism of action of fluralaner
Isoxazolines block the ligand-gated chloride channels of
both GABA and glutamate receptors [64, 67, 69]. Gene-
rally GABA receptors form cation channels while glu-
tamate receptors form anion channels and both are
critically important for effective invertebrate neuro-
transmission. The isoxazoline mode of action exhibits a
unique and selective inhibitory action of invertebrate
GABA and glutamate-gated chloride channels com-
pared with activity in mammalian neurons [65]. Anion
(inhibitory) glutamate channels are only found in inver-
tebrates, so this activity further increases the arthropod
specificity of fluralaner. In the invertebrate neurotransmis-
sion system, each ligand-gated chloride (anion) channel
mediates a fast inhibitory synaptic transmission through
the enhancement of chloride ion permeability through the
postsynaptic membrane, which subsequently leads to par-
alysis and death of fleas and ticks and other arthropods
[65, 78].
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The potential role of GABA receptors as an insecticidal
target was first shown in the 1980’s with the
organochlorines dieldrin and lindane [64, 79, 80]. However,
this opportunity for novel insecticidal or acaricidal activity
was not further developed until years later with the discov-
ery and commercial introduction of the phenylpyrazoles
(e.g. fipronil) formulated for topical administration only
and also distributed cutaneously [64]. However, fluralaner
shows a many fold higher receptor binding on arthropod
GABA-gated chloride channels than phenylpyrazoles [65].
Mode of action of fluralaner in dogs
After oral administration and absorption in the digestive
tract or topical administration and transdermal absorp-
tion, fluralaner is rapidly distributed by the circulatory
system and maximum plasma levels are on average
reached within 24 h after oral or approximately 7 days
after topical administration in dogs. The systemic distribu-
tion is quantitatively detectable in plasma (> 10 ng/ml) for
112 days post-treatment following oral administration,
thereby reflecting a long systemic persistence and a slow
elimination process in the dog, both apparently independ-
ent of dose [67, 72]. Furthermore, a high apparent volume
of distribution of fluralaner in tissues and a low clearance
rate [67] further contribute to the long-lasting systemic
availability of fluralaner in the dog. This persistent
availability has proved to deliver flea and tick killing ef-
ficacy for at least 12 weeks after a single oral or topical
administration [1, 81, 82].
Fluralaner delivers a potent ectoparasiticidal effect fol-
lowing ingestion by the parasite. Therefore, exposure to
the active ingredient occurs when the arthropod bites
the host and feeds on subcutaneous tissue fluids and
blood. The systemic distribution of fluralaner means that
there is no potential interference or other negative impact
on post-treatment efficacy associated with environmental
pressures (including bathing, shampooing, sun, rain, etc.)
that can potentially occur with cutaneously distributed
ectoparasiticides. Additionally, cross-contamination with
other household pets is not a concern. Topical administra-
tion of fluralaner (Bravecto Spot-On, MSD Animal Health,
Madison, USA) has been proved to be associated with no
influence on flea and tick efficacy in dogs that are either
immersed in water or shampooed between 3 and 84 days
after administration [83]. No data are published on dogs
immersed or shampooed before 3 days, although efficacy
was already 100 % against fleas and ticks (I. ricinus) at the
3 day test suggesting that the likely time of impact is well
before this time point [83].
Acaricidal efficacy of fluralaner
Immediate efficacy
Immediate efficacy results are important for eliminating
existing tick infestations to reduce owner concerns
regarding observation of tick infestations on their dogs
and for reducing the risk of transmission of tick-borne
infections [12]. A series of field and laboratory studies
demonstrated that a single dose of fluralaner adminis-
tered to dogs as a chewable tablet is highly efficacious
against common and important ectoparasitic Ixodiid
ticks infesting dogs including I. ricinus, I. scapularis, D.
reticulatus, D. variabilis, R. sanguineus and A ameri-
canum [1, 81, 82]. In addition, following oral fluralaner
administration, efficacy was demonstrated against the
Australian paralysis tick Ixodes holocyclus [84].
The rapid systemic distribution of fluralaner leads to a
targeted action on ticks through subcutaneous tissue
fluids and blood. Therefore, the tick is exposed to a
small but very potent dose of fluralaner on initial feeding
and is rapidly killed at an early stage following attach-
ment [85]. Investigations using tick weights and the
coxal index as a tick growth parameter showed that I.
ricinus ticks attached to fluralaner treated dogs did not
become engorged [86]. Experimental studies using adult
I. ricinus have shown tick killing activities of 89.6 % at
4 h, 97.9 % at 8 h, and 100 % at 12 and 24 h. Using tick
counts at 8 h after re-infestation, efficacy was 96.8 % at
4 weeks and 83.5 % at 8 weeks post-treatment, whereas
the efficacies at 12 and 24 h after re-infestation were at
least 98.1 % over the entire 12 week period [87]. A com-
parative study against R. sanguineus and D. reticulatus
following a 24 h exposure measured efficacy that de-
clined from 100 % at 30 days to 65.7 % at 84 days after a
single oral administration [88, 89]. Persistent fluralaner
efficacy of 100 % for 115 days when assessed 72 h after
treatment was measured against the Australian paraly-
sis tick I. holocyclus following a single oral dose of at
least 25 mg fluralaner [84]. High fluralaner acaricidal
activity was shown following 48 h exposure of imma-
ture R. sanguineus (s.l.) in an in vitro contact study and
by artificially feeding Ornithodorus moubata nymphs
[85]. Efficacy against juvenile tick stages has also been
observed under field conditions in Europe suggesting a
larger tick control spectrum for fluralaner [81].
Persistent efficacy of fluralaner against ticks
A single oral administration of fluralaner protected
dogs against > 99 % of European ticks including adult
R. sanguineus (s.l.), I. ricinus, I. hexagonus, D. reticula-
tus and nymphs and larvae of Ixodes spp. within 24 h
after treatment and for a period of 12 weeks under field
conditions [81, 87]. Similar potent tick-killing efficacy
(> 98 %) was measured against an experimental adult I.
ricinus infestation within a 12 to 24 h post-treatment
period for a period of 12 weeks after a single oral ad-
ministration of fluralaner [87]. No other systemic acari-
cidal treatment is commercially available that provides
this duration of protection [87]. The immediate and
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persistent tick killing efficacy is able to reduce the risk
of tick-borne infection transmission. This protective effect
was demonstrated in dogs that were administered a single
oral fluralaner dose and were then 100 % protected from
experimental challenge with B. canis-infected D. reti-
culatus ticks on days 2, 28, 56, 70 and 84 after treat-
ment. Exposed but untreated dogs in the 112 days
study became infected with B. canis demonstrating the
validity of the challenge [90].
Tick repellent activity of fluralaner
Fluralaner is a systemically distributed antiparasitic agent
and by definition is not repellent.
Flea efficacy of fluralaner
In vitro studies [65] found that fluralaner is highly effect-
ive against C. felis, Lucilia cuprina and Aedes aegypti
therefore demonstrating its insecticidal efficacy potential.
In vivo studies have measured immediate flea efficacy
detectable at 1 h post-treatment, with a significant dif-
ference from controls at 2 h and reaching between 99.4
and 100 % at 8, 12, 24 and 48 h after a single oral flura-
laner treatment [73, 91]. These efficacy results are proof
of rapid uptake and distribution of fluralaner following
oral administration [86].
Persistent fluralaner efficacy against fleas
Speed of kill studies with a single oral administration of
fluralaner treated dogs confirmed flea efficacy > 91 % at
4 h after re-infestation for 8 weeks after initial treatment
and efficacy ≥ 98 % at 8, 12 and 24 h after re-infestation
for a period of 12 weeks [73]. Sub-insecticidal blood con-
centrations (in an in vitro study) of 12.5 ng fluralaner/ml
led to a 100 % cessation of flea reproduction [86]. In vivo
experimental work following a single oral dose of flurala-
ner measured 100 % efficacy at 48 h after initial treatment
and following repeated C. felis infestations over 4 months
with a corresponding reduction of flea egg production
of 99.9 % [91]. All fleas were killed in less than 24 h on
fluralaner treated dogs [73] over a 12 week period after
treatment which is well before the expected onset of
egg laying. Therefore fluralaner treatment completely
prevents renewal of the flea population through egg-
laying into the environment as confirmed in a simulated
home environment and under experimental conditions
[91, 92]. A European multi-center field study [81] demon-
strated flea-control efficacies in privately owned dogs of
99.9 % for 12 weeks and 97.39 % of previously flea-
infested households were flea-free after this 12 week
period. A USA field study in treated dogs found that the
mean geometric flea count reduction was ≥ 99.7 % at 4, 8
and 12 weeks following a single oral fluralaner adminis-
tration [93]. In both of these field studies, alleviation of
associated flea-allergic dermatitis (FAD) clinical signs
was recorded.
Fluralaner flea repellent activity
As discussed previously, repellent activity is not thought
to be relevant for flea control. Fluralaner is a systemically
distributed antiparasitic agent and by definition does not
have repellent activity against arthropods.
Discussion on use of systemically versus cutaneously
distributed acaricides for reducing vector-borne infection
transmission risks
This review presents published data for both permethrin
as an example of a cutaneously distributed ectoparasiti-
cide treatment with proven repellency, and fluralaner as
an example of a systemically distributed ectoparasiticide.
Both options for ectoparasiticide control bring advan-
tages and disadvantages for ectoparasite treatment, as
can be seen from the data presented. In general, the
repellent treatment offers the potential to keep the
treated animal free of ectoparasites while minimizing
(but never eliminating) the risks associated with parasite
feeding. However, a tendency towards a slower onset of
efficacy; lack of rapid and uniform spread over the ani-
mal surface; the potential for loss from the skin surface
during the retreatment interval; variable activity against
different tick species; and declines in efficacy over the
retreatment interval are potential weaknesses for a cuta-
neously distributed repellent treatment. In contrast, the
systemically distributed treatment offers rapid and rela-
tively uniform distribution via blood circulation to all
body areas; faster onset of activity (although this could
vary depending on the potency of the systemically active
and distributed molecules considered); and the potential
for a longer duration of action (with the possible excep-
tion of cutaneously distributed treatments applied using
a slow release collar formulation). However, the flea or
tick is specifically targeted by the systemically distributed
treatment when it tries to feed. Therefore, it is not pos-
sible, based on the available published information, to
conclusively say that either treatment approach will be
superior to the other in all circumstances. Additionally,
there is evidence that different ixodid tick species have
variable sensitivities to both types of treatments.
Recognizing that neither treatment distribution
method can completely eliminate the risk of tick-borne
infection transmission under all circumstances and fur-
thermore that the question of comparative efficacy can
never be settled with a single experimental laboratory
challenge, what useful recommendations can be drawn
from this review?
First, veterinarians should continue to be careful to
counsel dog owners regarding additional actions to take
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to reduce the risk of tick-borne infection transmission,
along with the administration of an effective acaricide.
These additional actions are beyond the scope of this re-
view, and can include risk reduction activities such as
vaccination, avoiding high risk exposure areas, skin
examination, tick removal, and professional health
examination.
Secondly, in general, veterinarians could consider four
aspects of an acaricide with the goal of providing opti-
mal reduction in the risk of tick-borne disease transmis-
sion. These aspects are:
1. Owner adherence to the recommended treatment
protocol;
2. Rapid onset of activity following administration;
3. Uniform efficacy over all areas of the treated dog
at risk for parasite attachment; and
4. Maintenance of high efficacy throughout the
retreatment interval.
Each of these points is considered in more detail
below. Adherence refers to the dog owner’s obedience in
following the prescribed application instructions for the
pet’s medication. Lack of adherence is the most common
cause for efficacy failure of ectoparasiticide treatments
[94]. Owners may not follow through with prescribed
treatment recommendations because they are not seeing
ectoparasites at the time when retreatment is due; be-
cause they have concerns regarding their own exposure
to the treatment; because they are concerned that the
treatment could have an impact on their pet; because
they think that the risk of renewed ectoparasite infest-
ation is low; because they do not like the cosmetic
appearance of an external treatment application site; be-
cause their dog dislikes the sensation of treatment appli-
cation at the site; or, in the case of an oral medication, if
the dog is sensitive and regurgitates the medication.
Studies that have surveyed owners for their adherence
to cutaneously distributed treatment application instruc-
tions have found that owners tend to not follow direc-
tions. There are no similar surveys available yet with
regard to owner adherence to administration of systemic-
ally distributed treatments. If it is assumed that adherence
rates are equivalent for both approaches, then it follows
that the duration of the persistent efficacy of the product
becomes an important factor. Adherence failure only oc-
curs at the time when a retreatment should be adminis-
tered and a treatment with a longer persistent efficacy will
require fewer administrations. It is likely that ease of
treatment administration and the acceptance of the
treatment by the dog will be additional factors that
affect owner adherence to retreatment recommenda-
tions. These considerations may differ between individual
animals and the veterinarian may want to keep these
aspects in mind when considering whether to select an
orally or topically administered treatment.
Neither a systemically, nor cutaneously distributed
ectoparasiticide will have an inherently more rapid speed
of onset of activity. However, a systemically distributed
acaricide will have rapid circulation in the blood - and
uniform exposure to the ectoparasite in all areas of the
body. Therefore, the systemically distributed treatment
may be a better choice for this aspect.
The attached photograph (Fig. 2) shows Rhipicephalus
sanguineus (s.l.) ticks attached between the footpad of a
dog that was treated 7 days previously with a permethrin
combination product at a time when the treatment should
be providing peak efficacy (Fig. 1), and illustrates the diffi-
culties of delivering a cutaneously distributed treatment to
the extremities.
Persistent efficacy is very important because of the
need to maintain ectoparasiticide control throughout the
retreatment interval to reduce the arthropod-borne
disease transmission risk. A repellent treatment would
offer better reduction of tick-borne infection transmis-
sion if it could completely prevent all arthropods from
Fig. 2 Paw of a dog treated 7 days previously with a permethrin
combination product showing multiple attached Rhipicephalus sp.
ticks. Photo Dr M. Canfield, used with permission
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even trying to initiate feeding. Of course, for the flea it is
clear that the rapidity of feeding following infestation
precludes any benefit for a repellent treatment. However,
there is a potential opportunity to repel ticks before
feeding, and published efficacy data suggest that there is
a “sweet spot” following administration of an externally ac-
tive repellent product such as permethrin. This “sweet spot”
would be the time at which the product has achieved its
maximal dispersal over the epidermis before processes such
as desquamation, abrasion and environmental wetting have
reduced active ingredient levels - initially most likely in the
lower legs, axillae, tail and perianal areas. The exact timing
of this “sweet spot” is likely to vary and has not been
specifically measured, but the overall summary of efficacy
results for permethrin (Fig. 1) suggest that it is around
7–14 days following administration. The high level of
persistent efficacy observed following administration of
fluralaner shows that a systemically distributed treat-
ment can deliver persistent acaricidal efficacy as strong as
the comparable efficacy delivered by permethrin treatment
during the “sweet spot”. This efficacy can prevent trans-
mission of tick-borne infections such as B. canis [90];
however, this may not be true of all infections, or of all
systemic distributed acaricides.
Conclusions
No currently available acaricidal treatment can completely
prevent transmission of tick-borne diseases. However,
considering the factors of: owner adherence, immediate
efficacy, body surface area of protection, persistent efficacy
and adherence - a long lasting systemically distributed
acaricide can offer an optimal option with regard to redu-
cing tick-borne disease transmission risk. One additional
possibility may be to offer combination therapy with both
types of active ingredient – a possibility that remains to be
evaluated.
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